Study finds brain atrophy reduces in Lemtrada patients

[MSUK]

Genzyme has announced new magnetic resonance imaging (MRI) data from the Lemtrada clinical development program.

In relapsing remitting multiple sclerosis (RRMS) patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study (years three and four). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately 70 percent of Lemtrada patients did not receive additional Lemtrada treatment during the following three years, through month 48............. Read More - http://www.ms-uk.org/lemtrada